Mixed lineage kinase activity of indolocarbazole analoguesChikara Murakata, Robert L. Hudkins, Joanne R. Mathiasen et al.|Bioorganic & Medicinal Chemistry Letters|2002Cited by 94
Targeting the JNK Pathway for Therapeutic Benefit in CNS DiseaseDonna Bozyczko‐Coyne, Robert L. Hudkins, Michael S. Saporito|Current Drug Targets - CNS & Neurological Disorders|2002Cited by 69
CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting ActivitiesRita Raddatz, Michael Williams, Robert L. Hudkins et al.|Journal of Pharmacology and Experimental Therapeutics|2011Cited by 58
Mixed-Lineage Kinase 1 and Mixed-Lineage Kinase 3 Subtype-Selective Dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: Optimization, Mixed-Lineage Kinase 1 Crystallography, and Oral in Vivo Activity in 1-Methyl-4-phenyltetrahydropyridine ModelsRobert L. Hudkins, John P. Mallamo, James L. Diebold et al.|Journal of Medicinal Chemistry|2008Cited by 43